This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Diindolylmethane in Treating Patients With Stage I or Stage II Prostate Cancer Undergoing Radical Prostatectomy

This study has been completed.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Elisabeth Heath, Barbara Ann Karmanos Cancer Institute Identifier:
First received: April 24, 2009
Last updated: March 23, 2015
Last verified: March 2015

RATIONALE: The use of diindolylmethane, a substance found in cruciferous vegetables, may slow the growth of tumor cells.

PURPOSE: This phase II trial is studying how well diindolylmethane works in treating patients with stage I or stage II prostate cancer undergoing radical prostatectomy.

Condition Intervention Phase
Prostate Cancer Drug: B-Dim Procedure: Radical Prosatectomy Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Trial of B-DIM (DIM: 3,3 Diindolylmethane) on Intermediate Endpoint Biomarkers in Patients With Prostate Cancer Who Are Undergoing Prostatectomy

Resource links provided by NLM:

Further study details as provided by Elisabeth Heath, Barbara Ann Karmanos Cancer Institute:

Primary Outcome Measures:
  • Mean Level of Diindolylmethane in Prostate Tissue After Treatment [ Time Frame: Within the first 24 months after radical prostatectomy. ]

Secondary Outcome Measures:
  • Serum Levels of PSA, Testosterone,DIM Level and Diindolylmethane [ Time Frame: Pre and post radical prostatectomy ]
  • Levels of Androgen Receptor, NF-kB, and PSA in Prostate Tissue [ Time Frame: Pre and post radical prostatectomy ]

Enrollment: 39
Study Start Date: August 2009
Study Completion Date: April 2014
Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: B-Dim, Radical Prosatectomy

B-DIM 225 mg orally twice daily x 14-72 days (based on scheduling of surgery)

Radical Prostatectomy

Drug: B-Dim
B-DIM 225 mg orally twice daily x 14-72 days (based on scheduling of surgery)
Other Name: 3,3'-Diindolylmethane
Procedure: Radical Prosatectomy
Other Name: therapeutic conventional surgery

Detailed Description:



  • To measure the level of diindolylmethane in prostate tissue after treatment with oral microencapsulated diindolylmethane (B-DIM) in patients with stage I or II adenocarcinoma of the prostate undergoing radical prostatectomy.


  • To measure serum biomarkers (e.g., total PSA, serum testosterone, and diindolylmethane levels) pre- and post-treatment with B-DIM.
  • To measure tissue biomarkers (e.g., androgen receptor, NF-κB, and PSA) pre- and post-treatment with B-DIM.

OUTLINE: This is a multicenter study.

Patients receive oral microencapsulated diindolylmethane (B-DIM) twice daily for 14-72 days in the absence of disease progression or unacceptable toxicity. Patients then undergo radical prostatectomy 1 day after the last dose of B-DIM.

Patients undergo blood and tissue sample collection for correlative laboratory studies. Blood samples are analyzed for serum PSA, testosterone, and diindolylmethane levels by high performance liquid chromatography and tandem mass spectrometry (LC-MS/MS). Tissue samples are analyzed for diindolylmethane concentration by LC-MS/MS and for androgen receptor, activated NF-κB (p65 antibody), and PSA expression by IHC.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No


  • Histologically or cytologically confirmed adenocarcinoma of the prostate

    • Stage I or II (T1-T2 a, b, or c) disease
    • Disease confined to the prostate by clinical judgment of the surgeon
  • Deemed an appropriate candidate for surgery by clinical judgment of the surgeon


  • ECOG performance status 0-2
  • ANC ≥ 1,500/mm³
  • Platelet count ≥ 100,000/mm³
  • Hemoglobin ≥ 8.0 g/dL
  • Total bilirubin ≤ 1.5 times upper limit of normal (ULN)
  • AST and/or ALT ≤ 2.5 times ULN if alkaline phosphatase normal OR alkaline phosphatase ≤ 4 times ULN if AST and/or ALT normal
  • Serum creatinine ≤ 2.0 mg/dL
  • No history of allergic reactions attributed to compounds of similar chemical or biological composition to oral microencapsulated diindolylmethane
  • No concurrent uncontrolled illness including, but not limited to, any of the following:

    • Ongoing or active infection
    • Symptomatic congestive hart failure
    • Unstable angina pectoris
    • Cardiac arrhythmia
    • Psychiatric illness or social situation that would limit compliance with study requirements


  • No prior chemotherapy, hormonal therapy, brachytherapy, cryotherapy, external beam radiotherapy, or other therapy for prostate cancer
  • No concurrent micronutrient supplements or dietary soy products
  • No concurrent systemic therapy for any other cancer
  • No concurrent p450 inducers or inhibitors (e.g., carbamazepine, clarithromycin, fluconazole, fosphenytoin, itraconazole, ketoconazole, phenobarbital, phenytoin, rifabutin, or rifampin)
  • No concurrent finasteride or dutasteride
  • No other concurrent investigational or commercial agents or therapies for the malignancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00888654

United States, Michigan
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States, 48201-1379
Josephine Ford Cancer Center at Henry Ford Hospital
Detroit, Michigan, United States, 48202
Sponsors and Collaborators
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)
Principal Investigator: Elisabeth I. Heath, MD Barbara Ann Karmanos Cancer Institute
  More Information

Responsible Party: Elisabeth Heath, Principal Investigator, Barbara Ann Karmanos Cancer Institute Identifier: NCT00888654     History of Changes
Other Study ID Numbers: CDR0000641168
P30CA022453 ( U.S. NIH Grant/Contract )
Study First Received: April 24, 2009
Results First Received: March 23, 2015
Last Updated: March 23, 2015

Keywords provided by Elisabeth Heath, Barbara Ann Karmanos Cancer Institute:
adenocarcinoma of the prostate
stage I prostate cancer
stage II prostate cancer

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Anticarcinogenic Agents
Protective Agents
Physiological Effects of Drugs
Antineoplastic Agents processed this record on August 16, 2017